

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number
WO 01/26664 A2(51) International Patent Classification⁷: A61K 31/7088, C12N 9/20, C12Q 1/68, A61P 15/16

(74) Agents: GEORGIEV, Stephan, P. et al.; Smart & Biggar, Suite 3400, 1000 de la Gauchetiere Street West, Montreal, Quebec H3B 4W5 (CA).

(21) International Application Number: PCT/CA00/01228

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 13 October 2000 (13.10.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— Without international search report and to be republished upon receipt of that report.


(30) Priority Data:
2,286,451 14 October 1999 (14.10.1999) CA

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): HOPITAL SAINTE-JUSTINE [CA/CA]; 3175 Cote Sainte-Catherine Road, Montreal, Quebec H3T 1C5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MITCHELL, Grant, A. [CA/CA]; Division of Medical Genetics, Sainte-Justine Hospital, 3175 Cote Sainte-Catherine Road, Montreal, Quebec H3T 1C5 (CA). WANG, Shu, Pei [CA/CA]; Division of Medical Genetics, Sainte-Justine Hospital, 3175 Cote Sainte-Catherine Road, Montreal, Quebec H3T 1C5 (CA).



WO 01/26664 A2

(54) Title: HORMONE-SENSITIVE LIPASE MEDIATED MALE INFERTILITY

(57) Abstract: In various aspects, the invention provides pharmacologic and genomic methods of inhibiting fertility in a male animal, such as human male contraception, involving the manipulation of the activity of hormone-sensitive lipase, including inhibiting the activity of a hormone-sensitive lipase in the animal. In another aspect, the invention discloses the use of hormone-sensitive lipase as a target in screening assays that may be used to identify compounds that modulate male fertility. In another aspect, the present invention identifies a condition of male infertility caused by hormone-sensitive lipase deficiency.

HORMONE-SENSITIVE LIPASE MEDIATED MALE INFERTILITY

FIELD OF THE INVENTION

The invention is in the field of pharmacologic and genomic methods of male
5 contraception, involving the manipulation of the testicular activity of hormone-sensitive
lipase.

BACKGROUND OF THE INVENTION

There is a continuing need for methods of modulating male fertility. For example, in
10 humans, there is a need for alternatives to surgical approaches to male contraception such as
castration and vasectomy. There is also a new and growing need for methods of inhibiting
fertility in genetically modified organisms, as a means for preventing the dissemination of
genetic modifications into wild-type populations.

15 Hormone-sensitive lipase (E.C. 3.1.1.3) has several substrates, all of which are fatty
acyl esters. Hormone-sensitive lipase cleaves fatty acids from triacylglycerides and
diacylglycerides at the 1- and 3-positions, cholestryl esters and esters of retinoic acid and of
steroid hormones. Hormone-sensitive lipase is active in adipose tissue, where it plays an
important role in the release of fatty acids (Langin *et al.*, 1996, *Proceeding of the Nutrition
Society* 55:93). Hormone-sensitive lipase is also expressed in many non-adipose tissues, such
20 as adrenal gland, pancreatic beta cells, macrophages and testicles (Holst *et al.*, 1996,
Genomics 35:441; Mulder *et al.*, 1999, *Diabetes* 48:228; Reue *et al.*, 1997, *Arterioscler
Thromb Basic Biol* 17:3428; Blaise *et al.*, 1999, *J. Biol. Chem* 274:9327).

25 The human hormone-sensitive lipase gene has been cloned (Langin *et al.*, 1993, *Proc.
Natl. Acad. Sci USA* 90:4897). Hormone-sensitive lipase is an amphiphilic 84 Kda protein
with little homology to other mammalian lipases, containing three residues thought to be
essential for serine protease activity (Ser 424, Asp 693 and His 723). In testes, hormone-
sensitive lipase is expressed as a 130 KDa isoform, for which transcription begins in a
30 specific upstream exon that is spliced to a site 22 base pairs upstream of the initiation
methionine codon of nontesticular transcripts. The testicular hormone-sensitive lipase
isoform therefore contains all of the sequence of nontesticular hormone-sensitive lipase plus

an N-terminal extension encoded by the first (testes specific) exon. The testicular form of hormone-sensitive lipase is expressed at a specific phase of sperm development, in round and elongating spermatids.

5 A number of small molecule inhibitors of hormone-sensitive lipase are known, as shown in Table 1.

Table 1: Inhibitors of hormone-sensitive lipase

Inhibitor	IC50*
Diisopropylfluorophosphate (DFP)	9 microM
HgCl ₂ (mercuric chloride)	11 microM
NaF (sodium fluoride)	25 Mm

* concentration producing 50% inhibition (Stralfors *et al.*, 1987, *The Enzymes*, Vol. XVIII, 10 p.147-177, Academic Press)

SUMMARY OF THE INVENTION

In various aspects, the invention provides pharmacologic and genomic methods of 15 inhibiting fertility in a male animal, such as human male contraception, involving the manipulation of the activity of hormone-sensitive lipase, including inhibiting the activity of a hormone-sensitive lipase in the animal. In the context of the invention, inhibiting the activity of hormone-sensitive lipase includes reducing the activity of hormone-sensitive lipase by suppression of enzymatic activity or suppression of transcription or translation of hormone-20 sensitive lipase. In one aspect, genomic manipulations may be used to affect the expression of hormone-sensitive lipase, or to affect the activity of the expressed enzyme. In another aspect, pharmaceuticals may be administered to modulate the activity of hormone-sensitive lipase. In some aspects of the invention, a testicular isoform of hormone-sensitive lipase may be the target of pharmacologic or genomic modulation. In some aspects, the invention provides 25 methods of down-regulating testicular hormone-sensitive lipase to mediate male infertility by effecting the spermiogenesis phase of spermatogenesis. The method may for example comprise administering to the male animal an effective amount of a hormone-sensitive lipase inhibitor, which constitutes a use of a hormone-sensitive lipase inhibitor to inhibit fertility in a male animal.

In another aspect, the invention discloses the use of hormone-sensitive lipase as a target in screening assays that may be used to identify compounds that modulate male fertility. Such assays may be utilized to identify compounds that modulate expression of the hormone-sensitive lipase gene, or compounds that modulate the activity of the expressed enzyme. The testicular isoform of hormone-sensitive lipase may be used as the target in such assays. The use of a hormone-sensitive lipase in an assay to screen for a compound that inhibits male fertility may involve a method for identifying male fertility inhibitors comprising:

- 10 a) providing a test compound;
- b) providing a hormone-sensitive lipase;
- c) providing a substrate for the hormone-sensitive lipase;
- d) assaying the activity of the hormone-sensitive lipase on the substrate in the presence of the test compound, to identify test compounds that inhibit the hormone-sensitive lipase.

15 The method may further comprise the step of assaying the compounds for inhibition of male fertility, for example by inhibiting spermatogenesis.

In another aspect, the present invention identifies a condition of male infertility caused by hormone-sensitive lipase deficiency. A screening method is therefore provided to 20 provide information about testicular hormone-sensitive lipase activity in males. Such screening methods may be genomic or enzymatic, to screen respectively for expression or activity of hormone-sensitive lipase. Such screening methods may be used to identify individuals having reduced testicular hormone-sensitive lipase activity. Accordingly, a method of screening male patients, may comprise:

- 25 a) identifying a male patient having reduced fertility;
- b) assaying the activity of a testicular hormone-sensitive lipase in the male patient.

DETAILED DESCRIPTION OF THE INVENTION

30 In one aspect of the invention, genomic manipulations may be used to affect the expression of hormone-sensitive lipase. Germ line transformation with a gene targeting vector may for example be used to disrupt expression of functional hormone-sensitive lipase,

as described in Example 1. A wide variety of alternative genomic approaches are available to down-regulate the expression of functional hormone-sensitive lipase. For example, in alternative embodiments, transformation of cells with antisense constructs may be used to inhibit expression of hormone-sensitive lipase. Antisense constructs are nucleic acid

5 molecules that may be transcribed to provide an antisense molecule that is substantially complementary to all or a portion of the mRNA encoding a hormone-sensitive lipase, so that expression of the antisense construct interferes with the expression of the hormone-sensitive lipase. SEQ ID NO:1 is for example a putative human mRNA encoding the testicular isoform of hormone-sensitive lipase, with the putative coding sequence shown in SEQ ID NO:1 and

10 the protein sequence shown as SEQ ID NO: 2 (from Holst *et al.*, 1995, GenBank Accession No. NM_005357; see also Holst *et al.*, 1996, *Genomics* 35:441 and related GenBank Accession Nos. U40001 and U40002). In some embodiments, antisense constructs of the invention may therefore encode five or more contiguous nucleic acid residues substantially complimentary to a contiguous portion a nucleic acid sequence encoding a hormone-sensitive

15 lipase, such as SEQ ID NO:1 or another mRNA encoding a mammalian hormone-sensitive lipase. In one aspect of the invention, antisense constructs may be provided that encode a nucleic acid that is complementary to a testis-specific portion of a hormone-sensitive lipase mRNA, such as the testis-specific exon of the human testicular isoform of hormone-sensitive lipase (Holst *et al.*, 1996, *Genomics* 35:441).

20 Substantially complementary nucleic acids are nucleic acids in which the complement of one molecule is substantially identical to the other molecule. Two nucleic acid or protein sequences are considered substantially identical if, when optimally aligned, they share at least about 70% sequence identity. In alternative embodiments, sequence identity may for example be at least 75%, at least 90% or at least 95%. Optimal alignment of sequences for

25 comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman, 1981, *Adv. Appl. Math* 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, *J. Mol. Biol.* 48:443, the search for similarity method of Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85: 2444, and the computerised implementations of these algorithms (such as GAP, BESTFIT, FASTA and

30 TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be determined using the BLAST algorithm,

described in Altschul *et al.*, 1990, *J. Mol. Biol.* 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at <http://www.ncbi.nlm.nih.gov>). The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by

5 identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold. Initial neighbourhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be

10 increased. Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity

15 and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff, 1992, *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10 (or 1 or 0.1 or 0.01 or 0.001 or 0.0001), M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability

20 (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments of the invention, nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less

25 than about 0.001.

An alternative indication that two nucleic acid sequences are substantially complementary is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions. Hybridisation to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65EC, and washing in 0.2 x SSC/0.1% SDS at 42EC (see Ausubel, *et al.* (eds), 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green

Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3).

Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65EC, and washing in 0.1 x SSC/0.1% SDS at 68EC (see Ausubel, *et al.* (eds), 1989, *supra*). Hybridization

5 conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, *Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York). Generally, stringent conditions are selected to be about 5EC lower than the thermal melting point for the

10 specific sequence at a defined ionic strength and pH.

In alternative embodiments, the invention provides antisense molecules and ribozymes for exogenous administration to bind to, degrade and/or inhibit the translation of hormone-sensitive lipase mRNA. Examples of therapeutic antisense oligonucleotide applications,

15 incorporated herein by reference, include: U.S. Pat. No. 5,135,917, issued Aug. 4, 1992; U.S. Pat. No. 5,098,890, issued Mar. 24, 1992; U.S. Pat. No. 5,087,617, issued Feb. 11, 1992; U.S. Pat. No. 5,166,195 issued Nov. 24, 1992; U.S. Pat. No. 5,004,810, issued Apr. 2, 1991; U.S. Pat. No. 5,194,428, issued Mar. 16, 1993; U.S. Pat. No. 4,806,463, issued Feb. 21, 1989; U.S. Pat. No. 5,286,717 issued Feb. 15, 1994; U.S. Pat. No. 5,276,019 and U.S. Pat. No. 5,264,423;

20 BioWorld Today, Apr. 29, 1994, p. 3.

Preferably, in antisense molecules, there is a sufficient degree of complementarity to the hormone-sensitive lipase mRNA to avoid non-specific binding of the antisense molecule to non-target sequences under conditions in which specific binding is desired, such as under

25 physiological conditions in the case of in vivo assays or therapeutic treatment or, in the case of in vitro assays, under conditions in which the assays are conducted. The target mRNA for antisense binding may include not only the information to encode a protein, but also associated ribonucleotides, which for example form the 5'-untranslated region, the 3'-untranslated region, the 5' cap region and intron/exon junction ribonucleotides. A method of screening for antisense
30 and ribozyme nucleic acids that may be used to provide such molecules as hormone-sensitive lipase inhibitors of the invention is disclosed in U.S. Patent No. 5,932,435 (which is incorporated herein by reference).

Antisense molecules (oligonucleotides) of the invention may include those which contain intersugar backbone linkages such as phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages, phosphorothioates and those with $\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2$, $\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2$ (known as methylene(methylimino) or MMI backbone), $\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2$, $\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2$ and $\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2$ linkages (where phosphodiester is $\text{O}-\text{P}-\text{O}-\text{CH}_2$). Oligonucleotides having morpholino backbone structures may also be used (U.S. Pat. No. 5,034,506). In alternative embodiments, antisense oligonucleotides may have a peptide nucleic acid (PNA, sometimes referred to as "protein nucleic acid") backbone, in which the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone wherein nucleosidic bases are bound directly or indirectly to aza nitrogen atoms or methylene groups in the polyamide backbone (Nielsen *et al.*, 1991, *Science* 254:1497 and U.S. Pat. No. 5,539,082). The phosphodiester bonds may be substituted with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.

Oligonucleotides may also include species which include at least one modified nucleotide base. Thus, purines and pyrimidines other than those normally found in nature may be used. Similarly, modifications on the pentofuranosyl portion of the nucleotide subunits may also be effected. Examples of such modifications are 2'-O-alkyl- and 2'-halogen-substituted nucleotides. Some specific examples of modifications at the 2' position of sugar moieties which are useful in the present invention are OH, SH, SCH₃, F, OCN, O(CH₂)_n NH₂ or O(CH₂)_n CH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. One or more pentofuranosyl groups may be replaced by another sugar, by a sugar mimic such as cyclobutyl or by another moiety which takes the place of the sugar.

In some embodiments, the antisense oligonucleotides in accordance with this invention may comprise from about 5 to about 100 nucleotide units. As will be appreciated, a nucleotide unit is a base-sugar combination (or a combination of analogous structures) suitably bound to an adjacent nucleotide unit through phosphodiester or other bonds forming a backbone structure.

5

In another aspect, pharmaceuticals may be administered to modulate the activity of hormone-sensitive lipase. In this aspect of the invention, inhibitors of hormone-sensitive lipase may be selected from the group consisting of diisopropylfluorophosphate, mercuric chloride ($HgCl_2$) and sodium fluoride (NaF). In some aspects of the invention, a testicular isoform of hormone-sensitive lipase may be the target of pharmacologic or genomic modulation. For example, controlled-release formulations of hormone-sensitive lipase inhibitors may be administered to the testis or testicular region. In some aspects, the invention accordingly provides methods of down-regulating testicular hormone-sensitive lipase to mediate male infertility by affecting the spermiogenesis phase of spermatogenesis.

10

In another aspect, the invention discloses the use of hormone-sensitive lipase as a target in screening assays that may be used to identify compounds that modulate male fertility. In some embodiments, such an assay may comprise the steps of

- a) providing a test compound;
- 20 b) providing a hormone-sensitive lipase;
- c) providing a substrate for the hormone-sensitive lipase;
- d) assaying the activity of the hormone-sensitive lipase on the substrate in the presence of the compound, to identify compounds that inhibit the hormone-sensitive lipase.

25 Such an assay may further comprise the step of assaying the compounds for spermatogenesis or spermiogenesis inhibiting activity. Such assays may be utilized to identify compounds that modulate expression of the hormone-sensitive lipase gene, or compounds that modulate the activity of the expressed enzyme. The testicular isoform of hormone-sensitive lipase may be used as the target in such assays.

30

In one embodiment, screening assays of the invention may comprise identifying compounds that modulate the cholesteryl esterase activity of hormone-sensitive lipase. For

example, the neutral cholesteryl esterase activity of hormone-sensitive lipase may be assayed (Kraemer *et al.*, 1993, *J. Lipid Res.* 34:663). In alternative embodiments, lipolysis may be measured (Susulic *et al.*, 1995, *J. Biol. Chem.* 270:29483) with or without the addition of a lipolytic beta-3 adrenergic agonist, such as 10μM CL316,243 (Wyeth-Ayerst Research Laboratories, Princeton, NJ, USA).

5 In another aspect, the present invention identifies a condition of male infertility caused by hormone-sensitive lipase deficiency. A screening method is therefore provided to provide information about testicular hormone-sensitive lipase activity in males. Such 10 screening methods may be genomic or enzymatic, to screen respectively for expression or activity of hormone-sensitive lipase. Such methods are disclosed in Example 1. Such screening methods may be used to identify individuals having reduced testicular hormone-sensitive lipase activity.

15 Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers 20 defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.

25 **Example 1**

Murine transformation by blastocyst microinjection of a gene targeting vector was used to create chimeric mice having a functionally defective hormone-sensitive lipase allele. The mutant hormone-sensitive lipase allele lacked codons 2-172. The targeting vector was constructed from an *Af*II/*Bam*HI subclone of a murine genomic hormone-sensitive lipase 30 clone (Sztrolovics *et al.*, 1997, *Mamm Genome* 8:86). In the mutant allele, 513 coding base pairs in exon 1 and 1,494 base pairs in intron 1 were replaced with a promoterless beta galactosidase gene inserted in frame with the hormone-sensitive lipase coding sequences,

with a neomycin resistance cassette having a herpes simplex thymidine kinase promoter (pMC1Neo poly A, Stratagene).

5 Heterozygous F1 offspring of a male chimera with the mutant hormone-sensitive lipase allele and Balb/c females were crossed to produce mice for analysis. Germline transmission of the allele was obtained, and mice homozygous for the allele were produced.

Male hormone-sensitive-lipase-deficient mice having the defective hormone-sensitive lipase allele were completely infertile. Fertility was assessed by housing two month old males 10 for 5 days with two CD1 females, then separating the females for 5 days before rebreeding. Females not becoming pregnant were shown to be fertile by subsequent mating with controls. Wild-type mice from the same litter had normal fertility. Mating occurred at a similar rate in the wild-type and hormone-sensitive-lipase-deficient mice, as indicated by the presence of mucus plugs in females that were housed with the mice. Seminal vesicles from the hormone-15 sensitive-lipase-deficient mice were of normal weight and histology, suggesting that these mice are not androgen deficient. Testicles from mutant mice weighed about half as much as those from normal mice, this is consistent with a lack of spermatozoa since spermatozoa comprise about half of normal testicular weight. Histology confirmed this, revealing an absence of spermatozoa in the seminal vesicles and epididymis (i.e. azoospermia).
20 Spermatogenesis was similar in hormone-sensitive-lipase-deficient and wild-type mice during the development of mitotic (spermatogonia) and meiotic (spermatocyte) germ cells. In postmeiotic development (spermiogenesis) marked abnormalities were noted in the germ cells of hormone-sensitive-lipase-deficient mice, including the presence of large cytoplasmic masses near the tubular lumen, multi-nucleated spermatids, some sharing a common acrosome, disruption of the normal orientation of the heads of late spermatids, and by stage 25 VII of the seminiferous epithelial cycle a striking decrease in the number of late spermatids

30 Southern blot analysis showed that the hormone-sensitive-lipase-deficient allele was present in the transformed mice. Northern analysis (Wang *et al.*, 1993, *Mamm Genome* 4:382) using mouse cDNA probes from residues of 545-869 of the hormone-sensitive lipase gene showed that no normal hormone-sensitive lipase mRNA was expressed in these mice.

Cholesteryl esterase activity was undetectable in adipose tissue of mutant mice, consistent with a lack of functional hormone-sensitive lipase. Cholesteryl esterase activity was assayed as neutral cholesteryl esterase activity (Kraemer *et al.*, 1993, *J. Lipid Res.* 34:663). Perigonadal fat pad adipocytes were isolated (Shillabeer and Lau, 1994, *J. Lipid Res.* 35:592) and lipolysis measured (Susulic *et al.*, 1995, *J. Biol. Chem.* 270:29483) with or without the addition of 10µM lipolytic beta-3 adrenergic agonist CL316,243 (Wyeth-Ayerst Research Laboratories, Princeton, NJ, USA). For each mixture, triglyceride concentration was assayed, the diameters of 200 adipocytes were measured following fixation in 4% glutaraldehyde and the mean adipocyte lipid content, content and surface area calculated.

10

Six-month-old hormone-sensitive-lipase-deficient mice were grossly normal and similar to wild-type littermates in weight and adipose tissue histology. Plasma triglyceride and nonesterified fatty acids were lower in hormone-sensitive-lipase-deficient males. The mean diameter of adipocytes isolated from perigonadal fat pads of six-month old mice was 15 smaller in hormone-sensitive-lipase-deficient mice than in wild-type mice. When corrected for cell surface area, basal lipolysis in mutant adipocytes exceeded that of controls. Hormone-sensitive-lipase-deficient adipocytes lacked adrenergic responsiveness, in contrast to a 4- to 9-fold increase in wild-type adipocytes.

20 **Example 2: Therapeutic Formulations**

In various embodiments, hormone-sensitive lipase inhibitors may be used therapeutically in formulations or medicaments to inhibit male fertility. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a hormone-sensitive lipase inhibitor is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising an hormone-sensitive lipase inhibitor and a pharmacologically acceptable excipient or carrier. The therapeutic composition may be soluble in an aqueous solution at a physiologically acceptable pH.

30 The invention provides pharmaceutical compositions (medicaments) containing (comprising) hormone-sensitive lipase inhibitors. In one embodiment, such compositions include an hormone-sensitive lipase inhibitor in a therapeutically or prophylactically effective

amount sufficient to alter, and preferably inhibit, spermiogenesis, and a pharmaceutically acceptable carrier.

A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction or reversal of spermiogenesis, or reduction or inhibition male fertility. A therapeutically effective amount of hormone-sensitive lipase inhibitor may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of spermiogenesis or reducing male fertility. A prophylactically effective amount can be determined as described above for the therapeutically effective amount. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.

As used herein "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual or oral administration.

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, 5 glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the 10 composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the hormone-sensitive lipase inhibitors can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound 15 against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

20

Sterile injectable solutions can be prepared by incorporating the active compound (e.g. hormone-sensitive lipase inhibitor) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a 25 sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In accordance with an alternative aspect of 30 the invention, an hormone-sensitive lipase inhibitor may be formulated with one or more additional compounds that enhance the solubility of the hormone-sensitive lipase inhibitor.

In accordance with another aspect of the invention, therapeutic compositions of the present invention, comprising a hormone-sensitive lipase inhibitor, may be provided in containers having labels that provide instructions for use of the hormone-sensitive lipase inhibitor to inhibit male fertility or inhibit spermiogenesis.

5

WHAT IS CLAIMED IS:

1. A method of inhibiting fertility in a male animal comprising inhibiting the activity of a hormone-sensitive lipase in the animal.
5
2. The method of claim 1, wherein the hormone-sensitive lipase is a testicular hormone-sensitive lipase.
3. The method of claim 1 or 2, wherein the animal is a mammal.
10
4. The method of claim 1 or 2, wherein the animal is a human.
5. The method of claim 4, wherein the hormone-sensitive lipase has an amino acid sequence that is substantially identical to SEQ ID NO:2.
15
6. The method of claim 1, 2, 3, 4 or 5, wherein the method comprises inhibiting the expression of the hormone sensitive lipase.
7. The method of any one of claims 1 through 6, wherein the method comprises administering to the male animal an effective amount of a hormone-sensitive lipase inhibitor.
20
8. The method of claim 7, wherein the hormone-sensitive lipase inhibitor is an antisense molecule.
9. The method of claim 8 wherein the antisense molecule is a nucleic acid that is substantially complementary to a portion of an mRNA encoding a hormone-sensitive lipase.
25
- 30 10. The method of claim 9 wherein the mRNA is substantially identical to SEQ ID NO:1.

11. The method of claim 9 or 10 wherein the portion of the mRNA comprises at least 5 contiguous bases.
12. The use of a hormone-sensitive lipase in an assay to screen for a compound that 5 inhibits male fertility.
13. The use of a hormone-sensitive lipase according to claim 12, wherein the hormone-sensitive lipase is a testicular isoform of hormone-sensitive lipase.
- 10 14. The use of the hormone-sensitive lipase according to claim 12 or 13, wherein the hormone-sensitive lipase is a human hormone-sensitive lipase.
15. The use of the hormone-sensitive lipase according to claim 12, wherein the hormone-sensitive lipase has an amino acid sequence substantially identical to SEQ ID NO:2.
16. A method for identifying male fertility inhibitors comprising:
 - a) providing a test compound;
 - b) providing a hormone-sensitive lipase;
 - c) providing a substrate for the hormone-sensitive lipase;
 - 20 d) assaying the activity of the hormone-sensitive lipase on the substrate in the presence of the test compound, to identify test compounds that inhibit the hormone-sensitive lipase.
17. The method of claim 16, further comprising the step of assaying the compounds for 25 spermatogenesis inhibiting activity.
18. The method of claim 16 or 17, wherein the hormone-sensitive lipase is a testicular hormone-sensitive lipase.
- 30 19. The method of claim 16, 17 or 18, wherein the hormone-sensitive lipase is a mammalian hormone-sensitive lipase.

20. The method of any one of claims 16 through 19, wherein the hormone-sensitive lipase is a human hormone-sensitive lipase.
21. The method of any one of claims 16 through 19, wherein the hormone-sensitive lipase has an amino acid sequence substantially identical to SEQ ID NO:2.
22. A method of screening male patients, comprising:
 - a) identifying a male patient having reduced fertility;
 - b) assaying the activity of a testicular hormone-sensitive lipase in the male patient.
23. The use of a hormone-sensitive lipase inhibitor to inhibit fertility in a male animal.
24. The use of a hormone-sensitive lipase inhibitor according to claim 23, wherein the hormone-sensitive lipase inhibitor is an antisense molecule.
25. The use of a hormone-sensitive lipase inhibitor according to claim 24 wherein the antisense molecule is a nucleic acid that is substantially complementary to a portion of an mRNA encoding a hormone-sensitive lipase.
26. The use of a hormone-sensitive lipase inhibitor according to claim 25 wherein the mRNA is substantially identical to SEQ ID NO:1.
27. The use of a hormone-sensitive lipase inhibitor according to claim 25 or 26 wherein the portion of the mRNA comprises at least 5 contiguous bases.

1/11

SEQUENCE LISTING

<110> HOPITAL SAINTE-JUSTINE

MITCHELL, Grant A.

10 WANG, Shu Pei

<120> HORMONE-SENSITIVE LIPASE MEDIATED MALE INFERTILITY

<130> 86081-2

20

<140> PCT/CA 00/01228

<141> 2000-10-13

<150> CA 2,286,451

30 <151> 1999-10-14

<160> 2

<170> PatentIn version 3.0

40

<210> 1

<211> 3804

<212> RNA

<213> HOMO SAPIENS

50

<220>

<221> CDS

<222> (278) .. (3505)

60 <400> 1
cuucuuuguuaa gagagugcua ggcacauagc ccccuuccuau uccuaauccu cccacccaaag 60

2/11

aaagaggcac	agaguucauu	acuuaguggg	ggccagcugu	gaucggccaa	cugccagcug	120
ccuuaaaaag	gaagaccagu	gaugcuagga	uggagugaaa	cccaagagga	agugccauca	180
ugagggaauc	augagagauc	ugugaagaga	gagggcuggg	ugggagccca	gaaggauaga	240
accuggaaga	ucaaauaucuc	ccgugaggga	aauaaca	aug gag cca	ggu ucu aag	295
				Met Glu Pro	Gly Ser Lys	
				1	5	
10	uca gug ucu agg uca gac	ugg caa ccu gaa	cca cac cag	agg ccu aua	Ser Val Ser Arg Ser Asp Trp Gln Pro Glu Pro His Gln Arg Pro Ile	343
	10	15	20			
	acc ccg cua gag ccu ggg cca gaa aag aca ccc	aaa gca gcc cag cca gaa	Thr Pro Leu Glu Pro Gly Pro Glu Lys Thr Pro Ile Ala Gln Pro Glu	391		
	25	30	35			
20	ucg aag acu cug cag gga ucc aau acc caa cag	aag ccu gcu uca aac	Ser Lys Thr Leu Gln Gly Ser Asn Thr Gln Gln Lys Pro Ala Ser Asn	439		
	40	45	50			
	caa aga ccc cuc acc cag cag gag acc ccu gca caa cau gau gcu gaa	Gln Arg Pro Leu Thr Gln Gln Glu Thr Pro Ala Gln His Asp Ala Glu	487			
	55	60	65	70		
	ucc cag aag gaa ccu aga gcc caa caa aaa ucu gcu uca caa gag gaa	Ser Gln Lys Glu Pro Arg Ala Gln Gln Lys Ser Ala Ser Gln Glu Glu	535			
	75	80	85			
30	uuu cuu gcc cca cag aag ccc gca cca cag caa uca ccu uac auc caa	Phe Leu Ala Pro Gln Lys Pro Ala Pro Gln Gln Ser Pro Tyr Ile Gln	583			
	90	95	100			
	agg gug cug cuc acu caa cag gaa gcu gcc ucc cag cag gga ccu ggg	Arg Val Leu Leu Thr Gln Gln Glu Ala Ala Ser Gln Gln Gly Pro Gly	631			
	105	110	115			
40	cua gga aaa gaa ucu aua acu caa cag gag cca gca uug aga caa aga	Leu Gly Lys Glu Ser Ile Thr Gln Gln Glu Pro Ala Leu Arg Gln Arg	679			
	120	125	130			
	cau gua gcc cag cca ggg ccu ggg cca gga gag cca ccu cca gcu caa	His Val Ala Gln Pro Gly Pro Gly Glu Pro Pro Pro Ala Gln	727			
	135	140	145	150		
	caa gaa gcu gaa uca aca ccu gcg gcc cag gcu aaa ccu gga gcc aaa	Gln Glu Ala Glu Ser Thr Pro Ala Ala Gln Ala Lys Pro Gly Ala Lys	775			
	155	160	165			
50	agg gag cca ucu gcc ccg acu gaa ucu aca ucc caa gag aca ccu gaa	Arg Glu Pro Ser Ala Pro Thr Glu Ser Thr Ser Gln Glu Thr Pro Glu	823			
	170	175	180			
	cag uca gac aag caa aca acg cca guc cag gga gcc aaa ucc aag cag	Gln Ser Asp Lys Gln Thr Thr Pro Val Gln Gly Ala Lys Ser Lys Gln	871			
	185	190	195			
60	gga ucu uug aca gag cug gga uuu cua aca aaa cuu cag gaa cua ucc	Gly Ser Leu Thr Glu Leu Gly Phe Leu Thr Lys Leu Gln Glu Leu Ser	919			
	200	205	210			

215	220	225	230	967		
gau ucu gag uca gaa uca gau gug gga uca ucu uca gac aca gau ucu Asp Ser Glu Ser Glu Ser Asp Val Gly Ser Ser Ser Asp Thr Asp Ser 235 240 245					1015	
10	cca gcc acg aug ggu gga aug gug gcc cag gga gug aag cua ggc uuc Pro Ala Thr Met Gly Gly Met Val Ala Gln Gly Val Lys Leu Gly Phe 250 255 260					1063
aaa gga aaa ucu ggu uau aaa gug aug uca gga uac agu ggg acg ucg Lys Gly Lys Ser Gly Tyr Lys Val Met Ser Gly Tyr Ser Gly Thr Ser 265 270 275					1111	
20	cca cau gag aaa acc agu gcu cgg aau cac aga cac uac cag gau aca Pro His Glu Lys Thr Ser Ala Arg Asn His Arg His Tyr Gln Asp Thr 280 285 290					1159
gcc uca agg cuc auc cac aac aug gac cug cgc aca aug aca cag ucg Ala Ser Arg Leu Ile His Asn Met Asp Leu Arg Thr Met Thr Gln Ser 295 300 305 310					1207	
cug gug acu cug gcg gag gac aac aua gcc uuc uuc ucg agc cag ggu Leu Val Thr Leu Ala Glu Asp Asn Ile Ala Phe Phe Ser Ser Gln Gly 315 320 325					1255	
30	ccu ggg gaa acg gcc cag cgg cug uca ggc guu uuu gcc ggu gua cgg Pro Gly Glu Thr Ala Gln Arg Leu Ser Gly Val Phe Ala Gly Val Arg 330 335 340					1303
gag cag gcg cug ggg cug gag ccc gcc cug ggc cgc cug cug ggu gug Glu Gln Ala Leu Gly Leu Glu Pro Ala Leu Gly Arg Leu Leu Gly Val 345 350 355					1351	
40	gcg cac cuc uuu gac cug gac cca gag aca ccc gcc aac ggg uac cgc Ala His Leu Phe Asp Leu Asp Pro Glu Thr Pro Ala Asn Gly Tyr Arg 360 365 370					1399
agc cua gug cac aca gcc cgc ugc ugc cug gcg cac cuc cug cac aaa Ser Leu Val His Thr Ala Arg Cys Cys Leu Ala His Leu Leu His Lys 375 380 385 390					1447	
ucc cgc uau gug gcc ucc aac cgc cgc agc auc uuc uuc cgc acc agc Ser Arg Tyr Val Ala Ser Asn Arg Arg Ser Ile Phe Phe Arg Thr Ser 395 400 405					1495	
50	cac aac cug gcc gag cug gag gcc uac cug gcu gcc cuc acc cag cuc His Asn Leu Ala Glu Leu Glu Ala Tyr Leu Ala Ala Leu Thr Gln Leu 410 415 420					1543
cgc gcu cug guc uac uac gcc cag cgc cug cug guu acc aau cgg ccc Arg Ala Leu Val Tyr Tyr Ala Gln Arg Leu Leu Val Thr Asn Arg Pro 425 430 435					1591	
60	ggg gua cuc uuc uuu gag ggc gac gag ggg cuc acc gcc gac uuc cuc Gly Val Leu Phe Phe Glu Gly Asp Glu Gly Leu Thr Ala Asp Phe Leu 440 445 450					1639

4/11

cgg gag uau guc acg cug cau aag gga ugc uuc uau ggc cgc ugc cug Arg Glu Tyr Val Thr Leu His Lys Gly Cys Phe Tyr Gly Arg Cys Leu 455 460 465 470	1687
ggc uuc cag uuc acg ccu gcc auc cgg cca uuc cug cag acc auc ucc Gly Phe Gln Phe Thr Pro Ala Ile Arg Pro Phe Leu Gln Thr Ile Ser 475 480 485	1735
10 auu ggg cug gug ucc uuc ggg gag cac uac aaa cgc aac gag aca ggc Ile Gly Leu Val Ser Phe Gly Glu His Tyr Lys Arg Asn Glu Thr Gly 490 495 500	1783
cuc agu gug gcc gcc agc ucu cuc uuc acc agc ggc cgc uuu gcc auc Leu Ser Val Ala Ala Ser Ser Leu Phe Thr Ser Gly Arg Phe Ala Ile 505 510 515	1831
20 gac ccc gag cug cgu ggg gcu gag uuu gag cgg auc aca cag aac cug Asp Pro Glu Leu Arg Gly Ala Glu Phe Glu Arg Ile Thr Gln Asn Leu 520 525 530	1879
gac gug cac uuc ugg aaa gcc uuc ugg aac auc acc gag aug gaa gug Asp Val His Phe Trp Lys Ala Phe Trp Asn Ile Thr Glu Met Glu Val 535 540 545 550	1927
cua ucg ucu cug gcc aac aug gca ucg gcc acc gug agg gua agc cgc Leu Ser Ser Leu Ala Asn Met Ala Ser Ala Thr Val Arg Val Ser Arg 555 560 565	1975
30 cug cuc agc cug cca ccc gaa gcc uuu gag aug cca cug acu gcc gac Leu Leu Ser Leu Pro Pro Glu Ala Phe Glu Met Pro Leu Thr Ala Asp 570 575 580	2023
ccc acg cuc acg guc acc auc uca ccc cca cug gcc cac aca ggc ccu Pro Thr Leu Thr Val Thr Ile Ser Pro Pro Leu Ala His Thr Gly Pro 585 590 595	2071
40 ggg ccc guc cuc guc agg cuc auc ucc uau gac cug cgu gaa gga cag Gly Pro Val Leu Val Arg Leu Ile Ser Tyr Asp Leu Arg Glu Gly Gln 600 605 610	2119
gac agu gag gag cuc agc agc cug aua aag ucc aac ggc caa cgg agc Asp Ser Glu Glu Leu Ser Ser Leu Ile Lys Ser Asn Gly Gln Arg Ser 615 620 625 630	2167
cug gag cug ugg ccg cgc ccc cag cag gca ccc cgc ucg cgg ucc cug Leu Glu Leu Trp Pro Arg Pro Gln Gln Ala Pro Arg Ser Arg Ser Leu 635 640 645	2215
50 aua gug cac uuc cac ggc ggu ggc uuu gug gcc cag acc ucc aga ucc Ile Val His Phe His Gly Gly Phe Val Ala Gln Thr Ser Arg Ser 650 655 660	2263
cac gag ccc uac cuc aag agc ugg gcc cag gag cug ggc gcc ccc auc His Glu Pro Tyr Leu Lys Ser Trp Ala Gln Glu Leu Gly Ala Pro Ile 665 670 675	2311
auc ucc auc gac uac ucc cug gcc ccu gag gcc ccc uuc ccc cgu gcg Ile Ser Ile Asp Tyr Ser Leu Ala Pro Glu Ala Pro Phe Pro Arg Ala 680 685 690	2359

5/11

695	700	705	710	2407	
cug gag gag ugc uuc uuc gcc uac ugc ugg gcc auc aag cac ugc gcc Leu Glu Glu Cys Phe Phe Ala Tyr Cys Trp Ala Ile Lys His Cys Ala					
715	720	725		2455	
cuc cuu ggc uca aca ggg gaa cga auc ugc cuu gcg ggg gac agu gca Leu Leu Gly Ser Thr Gly Glu Arg Ile Cys Leu Ala Gly Asp Ser Ala					
10	730	735	740	2503	
ggc ggg aac cuc ugc uuc acc gug gcu cuu cgg gca gca gcc uac ggg Gly Gly Asn Leu Cys Phe Thr Val Ala Leu Arg Ala Ala Tyr Gly					
20	745	750	755	2551	
gug cgg gug cca gau ggc auc aug gca gcc uac ccg gcc aca aug cug Val Arg Val Pro Asp Gly Ile Met Ala Ala Tyr Pro Ala Thr Met Leu					
20	760	765	770	2599	
cag ccu gcc gcc ucu ccc ucc cgc cug cug agc cuc aug gac ccc uug Gln Pro Ala Ala Ser Pro Ser Arg Leu Leu Ser Leu Met Asp Pro Leu					
30	775	780	785	790	2647
cug ccc cuc agu gug cuc ucc aag ugu guc agc gcc uau gcu ggu gca Leu Pro Leu Ser Val Leu Ser Lys Cys Val Ser Ala Tyr Ala Gly Ala					
30	795	800	805	2695	
aag acg gag gac cac ucc aac uca gac cag aaa gcc cuc ggc aug aug Lys Thr Glu Asp His Ser Asn Ser Asp Gln Lys Ala Leu Gly Met Met					
40	810	815	820	2743	
ggg cug gug cgg cgg gac aca gcc cug cuc cuc cga gac uuc cgc cug Gly Leu Val Arg Arg Asp Thr Ala Leu Leu Arg Asp Phe Arg Leu					
40	825	830	835	2791	
ggu gcc ucc uca ugg cuc aac ucc uuc cug gag uua agu ggg cgc aag Gly Ala Ser Ser Trp Leu Asn Ser Phe Leu Glu Leu Ser Gly Arg Lys					
40	840	845	850	2839	
ucc cag aag aug ucg gag ccc aua gca gag ccg aug cgc cgc agu gug Ser Gln Lys Met Ser Glu Pro Ile Ala Glu Pro Met Arg Arg Ser Val					
50	855	860	865	870	2887
ucu gaa gca gca cug gcc cag ccc cag ggc cca cug ggc acg gau ucc Ser Glu Ala Ala Leu Ala Gln Pro Gln Gly Pro Leu Gly Thr Asp Ser					
50	875	880	885	2935	
cuc aag aac cug acc cug agg gac uug agc cug agg gga aac ucc gag Leu Lys Asn Leu Thr Leu Arg Asp Leu Ser Leu Arg Gly Asn Ser Glu					
50	890	895	900	2983	
acg ucg ucg gac acc ccc gag aug ucg cug uca gcu gag aca cuu agc Thr Ser Ser Asp Thr Pro Glu Met Ser Leu Ser Ala Glu Thr Leu Ser					
60	905	910	915	3031	
ccc ucc aca ccc ucc gau guc aac uuc uua uua cca ccu gag gau gca Pro Ser Thr Pro Ser Asp Val Asn Phe Leu Leu Pro Pro Glu Asp Ala					
60	920	925	930	3079	
ggg gaa gag gcu gag gcc aaa aau gag cug agc ccc aug gac aga ggc Gly Glu Glu Ala Glu Ala Lys Asn Glu Leu Ser Pro Met Asp Arg Gly					

6/11

935	940	945	950	3127
cug ggc guc cgu gcc uuc ccc gag ggu uuc cac ccc cga cgc ucc Leu Gly Val Arg Ala Ala Phe Pro Glu Gly Phe His Pro Arg Arg Ser				
955	960	965		3175
agc cag ggu gcc aca cag aug ccc cuc uac ucc uca ccc aua guc aag Ser Gln Gly Ala Thr Gln Met Pro Leu Tyr Ser Ser Pro Ile Val Lys				
10 970	975	980		3223
aac ccc uuc aug ucg ccg cug cug gca ccc gac agc aug cuc aag agc Asn Pro Phe Met Ser Pro Leu Leu Ala Pro Asp Ser Met Leu Lys Ser				
985	990	995		3271
cug cca ccu gug cac auc gug gcg ugc gcg cug gac ccc aug cug gac Leu Pro Pro Val His Ile Val Ala Cys Ala Leu Asp Pro Met Leu Asp				
1000	1005	1010		3316
20 1015	1020	1025		3361
gug acg cug cgc gug gug gag gac cug ccg cac ggc uuc cug acc Val Thr Leu Arg Val Val Glu Asp Leu Pro His Gly Phe Leu Thr				
1030	1035	1040		3406
cua gcg gcg cug ugc cgc gag acg cgc cag gcc gca gag cug ugc Leu Ala Ala Leu Cys Arg Glu Thr Arg Gln Ala Ala Glu Leu Cys				
30 1045	1050	1055		3451
gug gag cgc auc cgc cuc guc cuc acu ccu ccc gcc gga gcc ggg Val Glu Arg Ile Arg Leu Val Leu Thr Pro Pro Ala Gly Ala Gly				
1060	1065	1070		3496
ccg agc ggg gag acg ggg gcu gcg ggg gua gac ggg ggc ugc ggg Pro Ser Gly Glu Thr Gly Ala Ala Gly Val Asp Gly Gly Cys Gly				
40 1075				3545
ggg cga cac uaaaagccug uuguuuccau cugcgccggc cuccgucaug Gly Arg His				
50 1080				3605
aaugccuucc gggccggggcg gaaggggacg cgggcugugc uuacuuuagu cggggguggc				
aaggggggcg ggcggggggcc gaaagcugag acccucgcca cggggagggg gacgcgcaca				3665
cacaccgguc accgagacgg cuggaccugc acgccaccgc ugccuuuugc ugcugcugcu				3725
gcggcgaccg ccgcaggac ggggacuggc ccuuccuugc aggucgguuu gguuugguugu				3785
aaaaaaaagu auuuaauua				3804
<210> 2				
<211> 1076				
<212> PRT				
<213> HOMO SAPIENS				

7/11

<400> 2

Met Glu Pro Gly Ser Lys Ser Val Ser Arg Ser Asp Trp Gln Pro Glu
1 5 10 15

Pro His Gln Arg Pro Ile Thr Pro Leu Glu Pro Gly Pro Glu Lys Thr
20 25 30

10

Pro Ile Ala Gln Pro Glu Ser Lys Thr Leu Gln Gly Ser Asn Thr Gln
35 40 45

Gln Lys Pro Ala Ser Asn Gln Arg Pro Leu Thr Gln Gln Glu Thr Pro
50 55 60

20

Ala Gln His Asp Ala Glu Ser Gln Lys Glu Pro Arg Ala Gln Gln Lys
65 70 75 80

Ser Ala Ser Gln Glu Glu Phe Leu Ala Pro Gln Lys Pro Ala Pro Gln
85 90 95

Gln Ser Pro Tyr Ile Gln Arg Val Leu Leu Thr Gln Gln Glu Ala Ala
100 105 110

30

Ser Gln Gln Gly Pro Gly Leu Gly Lys Glu Ser Ile Thr Gln Gln Glu
115 120 125

Pro Ala Leu Arg Gln Arg His Val Ala Gln Pro Gly Pro Gly Pro Gly
130 135 140

40

Glu Pro Pro Pro Ala Gln Gln Glu Ala Glu Ser Thr Pro Ala Ala Gln
145 150 155 160

Ala Lys Pro Gly Ala Lys Arg Glu Pro Ser Ala Pro Thr Glu Ser Thr
165 170 175

Ser Gln Glu Thr Pro Glu Gln Ser Asp Lys Gln Thr Thr Pro Val Gln
180 185 190

50

Gly Ala Lys Ser Lys Gln Gly Ser Leu Thr Glu Leu Gly Phe Leu Thr
195 200 205

Lys Leu Gln Glu Leu Ser Ile Gln Arg Ser Ala Leu Glu Trp Lys Ala
210 215 220

Leu Ser Glu Trp Val Ala Asp Ser Glu Ser Glu Ser Asp Val Gly Ser
60 225 230 235 240

8/11

Ser Ser Asp Thr Asp Ser Pro Ala Thr Met Gly Gly Met Val Ala Gln
245 250 255

Gly Val Lys Leu Gly Phe Lys Gly Lys Ser Gly Tyr Lys Val Met Ser
260 265 270

10 Gly Tyr Ser Gly Thr Ser Pro His Glu Lys Thr Ser Ala Arg Asn His
275 280 285

Arg His Tyr Gln Asp Thr Ala Ser Arg Leu Ile His Asn Met Asp Leu
290 295 300

20 Arg Thr Met Thr Gln Ser Leu Val Thr Leu Ala Glu Asp Asn Ile Ala
305 310 315 320

Phe Phe Ser Ser Gln Gly Pro Gly Glu Thr Ala Gln Arg Leu Ser Gly
325 330 335

Val Phe Ala Gly Val Arg Glu Gln Ala Leu Gly Leu Glu Pro Ala Leu
340 345 350

30 Gly Arg Leu Leu Gly Val Ala His Leu Phe Asp Leu Asp Pro Glu Thr
355 360 365

Pro Ala Asn Gly Tyr Arg Ser Leu Val His Thr Ala Arg Cys Cys Leu
370 375 380

40 Ala His Leu Leu His Lys Ser Arg Tyr Val Ala Ser Asn Arg Arg Ser
385 390 395 400

Ile Phe Phe Arg Thr Ser His Asn Leu Ala Glu Leu Glu Ala Tyr Leu
405 410 415

Ala Ala Leu Thr Gln Leu Arg Ala Leu Val Tyr Tyr Ala Gln Arg Leu
420 425 430

50 Leu Val Thr Asn Arg Pro Gly Val Leu Phe Phe Glu Gly Asp Glu Gly
435 440 445

Leu Thr Ala Asp Phe Leu Arg Glu Tyr Val Thr Leu His Lys Gly Cys
450 455 460

60 Phe Tyr Gly Arg Cys Leu Gly Phe Gln Phe Thr Pro Ala Ile Arg Pro
465 470 475 480

9/11

Phe Leu Gln Thr Ile Ser Ile Gly Leu Val Ser Phe Gly Glu His Tyr
 485 490 495

Lys Arg Asn Glu Thr Gly Leu Ser Val Ala Ala Ser Ser Leu Phe Thr
 500 505 510

10 Ser Gly Arg Phe Ala Ile Asp Pro Glu Leu Arg Gly Ala Glu Phe Glu
 515 520 525

Arg Ile Thr Gln Asn Leu Asp Val His Phe Trp Lys Ala Phe Trp Asn
 530 535 540

Ile Thr Glu Met Glu Val Leu Ser Ser Leu Ala Asn Met Ala Ser Ala
 545 550 555 560

20 Thr Val Arg Val Ser Arg Leu Leu Ser Leu Pro Pro Glu Ala Phe Glu
 565 570 575

Met Pro Leu Thr Ala Asp Pro Thr Leu Thr Val Thr Ile Ser Pro Pro
 580 585 590

30 Leu Ala His Thr Gly Pro Gly Pro Val Leu Val Arg Leu Ile Ser Tyr
 595 600 605

Asp Leu Arg Glu Gly Gln Asp Ser Glu Glu Leu Ser Ser Leu Ile Lys
 610 615 620

Ser Asn Gly Gln Arg Ser Leu Glu Leu Trp Pro Arg Pro Gln Gln Ala
 625 630 635 640

40 Pro Arg Ser Arg Ser Leu Ile Val His Phe His Gly Gly Phe Val
 645 650 655

Ala Gln Thr Ser Arg Ser His Glu Pro Tyr Leu Lys Ser Trp Ala Gln
 660 665 670

50 Glu Leu Gly Ala Pro Ile Ile Ser Ile Asp Tyr Ser Leu Ala Pro Glu
 675 680 685

Ala Pro Phe Pro Arg Ala Leu Glu Glu Cys Phe Phe Ala Tyr Cys Trp
 690 695 700

Ala Ile Lys His Cys Ala Leu Leu Gly Ser Thr Gly Glu Arg Ile Cys
 705 710 715 720

10/11

Leu Ala Gly Asp Ser Ala Gly Gly Asn Leu Cys Phe Thr Val Ala Leu
 725 730 735

Arg Ala Ala Ala Tyr Gly Val Arg Val Pro Asp Gly Ile Met Ala Ala
 740 745 750

10 Tyr Pro Ala Thr Met Leu Gln Pro Ala Ala Ser Pro Ser Arg Leu Leu
 755 760 765

Ser Leu Met Asp Pro Leu Leu Pro Leu Ser Val Leu Ser Lys Cys Val
 770 775 780

20 Ser Ala Tyr Ala Gly Ala Lys Thr Glu Asp His Ser Asn Ser Asp Gln
 785 790 795 800

Lys Ala Leu Gly Met Met Gly Leu Val Arg Arg Asp Thr Ala Leu Leu
 805 810 815

Leu Arg Asp Phe Arg Leu Gly Ala Ser Ser Trp Leu Asn Ser Phe Leu
 820 825 830

30 Glu Leu Ser Gly Arg Lys Ser Gln Lys Met Ser Glu Pro Ile Ala Glu
 835 840 845

Pro Met Arg Arg Ser Val Ser Glu Ala Ala Leu Ala Gln Pro Gln Gly
 850 855 860

40 Pro Leu Gly Thr Asp Ser Leu Lys Asn Leu Thr Leu Arg Asp Leu Ser
 865 870 875 880

Leu Arg Gly Asn Ser Glu Thr Ser Ser Asp Thr Pro Glu Met Ser Leu
 885 890 895

Ser Ala Glu Thr Leu Ser Pro Ser Thr Pro Ser Asp Val Asn Phe Leu
 900 905 910

50 Leu Pro Pro Glu Asp Ala Gly Glu Glu Ala Glu Ala Lys Asn Glu Leu
 915 920 925

Ser Pro Met Asp Arg Gly Leu Gly Val Arg Ala Ala Phe Pro Glu Gly
 930 935 940

Phe His Pro Arg Arg Ser Ser Gln Gly Ala Thr Gln Met Pro Leu Tyr
 945 950 955 960

60

11/11

Ser Ser Pro Ile Val Lys Asn Pro Phe Met Ser Pro Leu Leu Ala Pro
965 970 975

Asp Ser Met Leu Lys Ser Leu Pro Pro Val His Ile Val Ala Cys Ala
980 985 990

10 Leu Asp Pro Met Leu Asp Asp Ser Val Met Leu Ala Arg Arg Leu Arg
995 1000 1005

Asn Leu Gly Gln Pro Val Thr Leu Arg Val Val Glu Asp Leu Pro
1010 1015 1020

His Gly Phe Leu Thr Leu Ala Ala Leu Cys Arg Glu Thr Arg Gln
1025 1030 1035

20 Ala Ala Glu Leu Cys Val Glu Arg Ile Arg Leu Val Leu Thr Pro
1040 1045 1050

Pro Ala Gly Ala Gly Pro Ser Gly Glu Thr Gly Ala Ala Gly Val
1055 1060 1065

30 Asp Gly Gly Cys Gly Gly Arg His
1070 1075